Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma.

Published 08/21/2026

Research record: Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma.

Published in J Vis Exp; first publication date 2026-08-21. PMID 42631614.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-08-21

Updated

2026-10-20

Disclaimer

professional use

References